Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PERI -37.7% (guidance), UMC -0.6% (March revs)
Other news:
- ITOS -7.5% (Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024)
- EDAP -4.4% (files for US$125 mln mixed securities shelf offering)
- HOWL -3.7% (Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting)
- ALKS -2.8% (Presents Analyses From Long-Term Safety Study of LYBALVI)
- PWFL -2.1% (announces restatement of accounting treatment of legacy convertible preferred stock instrument, which has no adverse impact on previously reported revenue, cash flow or adjusted EBITDA)
- WIT -1.2% (appoints Srini Pallia as CEO)
- UAL -1.1% (after Investor Day)
- BIP -0.8% (files mixed securities shelf offering)
Analyst comments:
- NRGV -2.9% (downgraded to Sell from Buy at Chardan Capital Markets)
- GFS -1.4% (downgraded to Neutral from Overweight at Cantor Fitzgerald)
- KR -1% (downgraded to Underperform from Neutral at Exane BNP Paribas)